Banyan Development

Banyan Biomarkers is a specialized biotechnology company focused on the development and commercialization of diagnostic tests for traumatic brain injury (TBI). The company's flagship product, the Banyan BTI (Brain Trauma Indicator), is the first FDA-cleared blood test used to evaluate patients with suspected mild TBI or concussion. By measuring the levels of two specific protein biomarkers, UCH-L1 and GFAP, that are released into the bloodstream following a brain injury, the test helps clinicians determine the need for a CT scan. Banyan Biomarkers continues to leverage its expertise in neuro-biomarkers to expand its diagnostic pipeline for various neurological conditions and brain injuries.